



January 6, 2020


Re: SECURE-IBD COVID-19 update #20

Dear Colleagues,

We hope this newsletter finds you safe and well. Despite the current chaos, we hope that 2021 will bring us all good health and peace. The number of COVID-19 cases reported to SECURE-IBD continues to rise at an accelerated rate. As of January 5, 2021, there have been 4,280 COVID-19 cases in IBD patients reported in SECURE-IBD from 63 countries. We hope that the global population is vaccinated soon and this pandemic is brought under control.

After the success of the first round of applications for ancillary studies using de-identified SECURE-IBD data, we are currently accepting a second round of applications until Friday, January 18, 2021. Please share this information with interested colleagues, trainees and especially students. We have submitted manuscripts on the [COVID-19 Risk Calculator](#), disparities in outcomes by race and ethnicity, impact of comorbid conditions and temporal trends in COVID-19 reporting in SECURE-IBD database. Ongoing studies include those on GI symptoms of COVID-19 and outcomes with vedolizumab use.

Please continue to spread the word about SECURE-IBD to all of your colleagues, locally, nationally, and internationally!



Interactive web-based map: <http://covidibd.org/map/>

You may download flyers translated into 17 languages at <https://covidibd.org/press/>

Frequently Asked Questions

What is SECURE-IBD? Surveillance Epidemiology of Coronavirus) Under Research Exclusion (SECURE-IBD) is an international, pediatric and adult registry to monitor and report on outcomes of COVID-19 occurring in IBD patients. The registry contains only de-identified data, in accordance with [HIPAA Safe Harbor De-Identification standards](#). The UNC-Chapel Hill Office for Human Research Ethics has determined that storage and analysis of de-identified data does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102] and does not require IRB approval.

How can a provider report a case? We encourage **all IBD providers to report all cases of confirmed COVID-19** in IBD patients, regardless of severity. Reporting should take at most 5 minutes. Please report only confirmed COVID-19 cases,

and report after a minimum of 7 days from COVID diagnosis and sufficient time has passed to observe the disease course through resolution of acute illness or death. To report a case of coronavirus, click [here](#)

Who is organizing this project? This project is being led by Drs. Michael Kappelman (Pediatric Gastroenterologist) and Erica Brenner (Pediatric Gastroenterology fellow) at the University of North Carolina at Chapel Hill and Dr. Ryan Ungaro (Gastroenterologist), Dr. Manasi Agrawal (Gastroenterologist) and Dr. Jean-Frederic Colombel (Gastroenterologist) at the Icahn School of Medicine at Mount Sinai, New York.

Are there any partnering organizations/societies? Official partners include the Crohn's & Colitis Foundation, the International Organization for the Study of IBD (IOIBD), the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), the European Crohn's and Colitis Organisation (ECCO), the Asian Organization for Crohn's & Colitis, and the Pan American Crohn's and Colitis Organisation (PANCCO). We also acknowledge the promotional support of many local/regional societies and pharmaceutical companies as detailed on www.covidibd.org.



European
Crohn's and Colitis
Organisation



Please visit us at www.covidibd.org for updated information or to report a case.

Follow us on Twitter: @SecureIBD

If you have any questions, please reach out to COVID.IBD@unc.edu.

Through worldwide collaboration, we can make a large difference!

Best,

Mike, Erica, Jean-Fred, Ryan and Manasi

Advisory Committee Members

North America: Jim Lewis and Gil Kaplan

Nursing and Advanced Practitioners: Michele Kissous-Hunt

Europe: Walter Reinisch and Jean-Francois Rahier

Asia: Siew Ng

S. America: Flavio Steinwurz

Australia/New Zealand: Richard Gearry

Industry: Irene Modesto

IOIBD: Marischka Konings